多肿瘤标志物蛋白芯片检测系统临床应用评价  

Clinical evaluation for protein chip system of multi-tumor marker detection

作　　者：符本琪[1] 刘献华[1] 佘炜[1] 宋文忠[1] 唐振林[1] 

机构地区：[1]四川省人民医院核医学科,四川成都610072

出　　处：《实用医院临床杂志》2006年第2期34-35,共2页Practical Journal of Clinical Medicine

摘　　要：目的 探讨多肿瘤标志物蛋白芯片检测系统（C-12系统）在临床应用中的价值。方法采用C-12系统,对临床常见的10种恶性肿瘤患者114例及对照组（健康人群52例和良性痰病患者32例）的血清进行检测，评价其敏感性、特异性、准确度、阳性预测值厦阴性预测值。同一样本分别采用化学发光分析、时间分辨荧光免疫分析、IRMA进行相同项目的测定，评价该系统与其它检测方法的相关性。结果恶性肿瘤患者114例中。阳性106例，敏感性为92．9％；时照组84例中，阳性19例，特异性为77．4％；准确度为86．4％；阳性预测值为84．8％；阴性预测值为89．0％。C-12系统检测值与其它检测方法呈正相关关系（r=0．494～0．895，P〈0．001）。结论多肿瘤标志物蛋白芯片检测系统可用于临床肿瘤实验室诊断和疗效观察，更适宜于健康体检及肿瘤普查。Objective To study the clinical value of protein chip system in the detection of multi-tumor markers （ C-12 system）. Methods The serums of 114 malignant tumour patients, 32 benign disease patients and 52 healthy subjects were detected by C-12 system. The sensitivity, specificity, accuracy, positive predictive value and negative predictive value of C-12 system were analyzed. The results of C-12 system were compared with those of chemiluminescence immunoassay, DELFIA and IRMAt and the correlation between C-12 system and the others was evaluated. Results Among the 114 malignant tumour patients, 106 were positive, while 19 were positive among 84 controls. The sensitivity, specificity, accuracy, positive predictive value and negative predictive value of C-12 system were 92.9% , 77.4%, 86.4%, 84.8%, 89.0%, respectively. There was significant positive correlation between the results of C-12 system and the others （ r =0.494-0. 895, P 〈 0. 001 ）. Conclusion C-12 system is appropriate for clinical diagnosis and outcome prediction of tumours, particularly for tumour screening of healthy group.

关 键 词：肿瘤标志物 蛋白芯片 

分 类 号：R730.43[医药卫生—肿瘤]